Substituted cathinone products: A new trend in "bath salts" and other designer stimulant drug use

Journal of Addiction Medicine

Volumn 7, Issue 3, 2013, Pages 153-162

  Gunderson, Erik W ^a,b,c   Kirkpatrick, Matthew G ^d   Willing, Laura M ^e   Holstege, Christopher P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Center for Wellness and Change   (United States)

^c College of Physicians and Surgeons ^*  (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bath salts; Cathinone; Designer drug; Mephedrone; Methylenedioxypyrovalerone (MDPV); Review

Indexed keywords

4' METHYLMETHCATHINONE; AMPHETAMINE; CATHINONE; COCAINE; DIAZEPAM; DOMESTIC CHEMICAL; LORAZEPAM; METHYLENEDIOXYPYROVALERONE; METHYLONE; MIDAZOLAM; PSYCHOSTIMULANT AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ALKALOID; CENTRAL STIMULANT AGENT; DESIGNER DRUG; INORGANIC SALT;

ACUTE TOXICITY; AGITATION; CHEMICAL COMPOSITION; CHRONIC TOXICITY; CONFUSION; COST BENEFIT ANALYSIS; DELUSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; HALLUCINATION; HUMAN; HYPERTENSION; LEGAL ASPECT; LOW DRUG DOSE; MARKETING; MYDRIASIS; MYOCLONUS; MYOCLONUS SEIZURE; NONHUMAN; PARANOIA; POLICY; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; TREMOR; TREND STUDY; UNITED STATES; VIOLENCE; ADDICTION; BATH; CLASSIFICATION; DRUG CONTROL; HEALTH; METABOLISM; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PACKAGING; PATHOPHYSIOLOGY; POISON CENTER; SOCIAL MARKETING; STATISTICS;

ALKALOIDS; BATHS; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIGNER DRUGS; DRUG AND NARCOTIC CONTROL; HUMANS; POISON CONTROL CENTERS; PRODUCT LABELING; SALTS; SOCIAL MARKETING; SUBSTANCE-RELATED DISORDERS; WORLD HEALTH;

MLCS; MLOWN;

EID: 84881006291     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31829084b7     Document Type: Review

References (81)

1. Advisory Council on the Misuse of Drugs. ACMD report on the consideration of the cathinones. 2010. Available at: http://www.homeoffice. gov. uk/acmd1/acmd-cathinodes-report-2010. Accessed December 28, 2012.
2. American Association of Poison Control Centers. Bath Salts Data. February 28, 2013. Available at: https://aapcc.s3.amazonaws.com/files/library/Bath- Salts-Data-for-Website-2.282013.pdf. Accessed April 3, 2013.
3. Antonowicz JL, Metzger AK, Ramanujam SL. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psychiatry 2011;33(6):640.e5-640.e6.
4. Baumann MH, Ayestas M A Jr, Partilla JS, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012;37(5):1192-1203.
5. Baumann MH, Partilla JS, Lehner KR, et al. Powerful cocaine-like actions of 3, 4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology. 2013;38(4):552-62.
6. BBC News. Selkirk man Greg Alexander died after mephedrone 'bomb.' January 17, 2012. Available at: http://www.bbc.co.uk/news/mobile/ukscotland- south-scotland-16592023. Accessed December 28, 2012.
7. Bedi G, Hyman D, De Wit H. Is ecstasy an "empathogen"? Effects of +/-3, 4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry 2010;68(12):1134-1140.
8. Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3, 4-methylenedioxypyrovalerone. Ann Emerg Med 2012;60(1):103-105.
9. Brandt SD, Sumnall HR, Measham F, et al. Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test Anal 2010;2(8):377-382.
10. Bronstein AC, Spyker DA, Cantilena L R Jr et al. 2009 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th annual report. Clin Toxicol (Phila) 2010;48(10):979-1178.
11. Cameron KN, Kolanos R, Solis E, et al. Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol. 2013;168(7):1750-7.
12. Carhart-Harris RL, King LA, Nutt DJ. A Web-based survey on mephedrone. Drug Alcohol Depend 2011;118(1):19-22.
13. Carvalho M, Carmo H, Costa VM, et al. Toxicity of amphetamines: an update. Arch Toxicol 2012;86(8):1167-1231.
14. Centers for Disease Control and Prevention. Emergency department visits after use of a drug sold as "bath salts"-Michigan, November 13, 2010-March 31, 2011. MMWR Morb Mortal Wkly Rep 2011;60(19):624-627.
15. Coppola M, Mondola R. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food." Toxicol Lett 2012;211(2):144-149.
16. Cox G, Rampes H. Adverse effects of khat: a review. Adv Psychiatr Treat 2003;9:456-463.
17. Cozzi NV, Sievert MK, Shulgin AT, et al. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 1999;381(1):63-69.
18. Dal Cason TA, Young R, Glennon RA. Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol Biochem Behav. 1997 Dec; 58(4):1109-16.
19. Dargan PI, Albert S, Wood DM. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 2010;103(11):875-879.
20. Davies S, Wood DM, Smith G, et al. Purchasing 'legal highs' on the Internet-is there consistency in what you get? QJM 2010;103(7):489-493.
21. Dorairaj JJ, Healy C, McMenamin M, et al. The untold truth about "bath salt" highs: a case series demonstrating local tissue injury. J Plast Reconstr Aesthet Surg 2012;65(2):e37-e41.
22. Drug Enforcement Administration, Office of Diversion Control. Drug and chemical evaluation section: methylenedeoxypyrovalerone [(MDPV) (1-(1, 3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone]. Springfield, VA: US Drug Enforcement Administration, 2010.
23. Drug Enforcement Administration, Office of Diversion Control. National Forensic Laboratory Information System special report: synthetic cannabinoids and synthetic cathinones reported in NFLIS, 2009-2010. Springfield, VA: US Drug Enforcement Administration, 2011a. Available at: https://www.nflis.deadiversion. usdoj.gov/DesktopModules/ReportDownloads/Reports/SynCannabSynCath.pdf. Accessed December 28, 2012.
24. Drug Enforcement Agency, Office of Diversion Control, Drug and Chemical Evaluation Section. Background, data and analysis of synthetic cathinones: mephedrone (4-MMC), methylone (MDMC) and 3, 4-methylenedioxypyrovalerone (MDPV). Springfield, VA: US Drug Enforcement Administration, 2011b.
25. Drug Enforcement Agency, Office of Forensic Sciences. Notice of intent: schedules of controlled substances: temporary placement of three synthetic cathinones into schedule I. Microgram Bull 2011c; 44(9):57-66. Available at: http://www.justice.gov/dea/pr/micrograms/2011/mg0911.pdf. Accessed December 28, 2012.
26. Fleckenstein AE, Haughey HM, Metzger RR, et al. Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur J Pharmacol 1999;382(1):45-49.
27. Freeman TP, Morgan CJ, Vaughn-Jones J, et al. Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. Addiction 2012;107(4):792-800.
28. Frison G, Gregio M, Zamengo L, et al. Gas chromatography/mass spectrometry determination of mephedrone in drug seizures after derivatization with 2, 2, 2-trichloroethyl chloroformate. Rapid Commun Mass Spectrom 2011;25(2):387-390.
29. Google Trends (2013a). Available at: http://www.google.com/trends/ explore#q=mephedrone Accessed April 3, 2013.
30. Google Trends (2013b). Available at: http://www.google.com/trends/ explore#q=bath%20salts Accessed April 3, 2013.
31. Gunderson EW, Haughey HM, Ait-Daoud N, et al. "Spice" and "K2" herbal highs: a case series and review illustrating the pharmacological and biopsychosocial implications of synthetic cannabinoid use. Am J Addict 2012;21(4):320-326.
32. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008;23:15-26.
33. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011;49(8):705-719.
34. Hitt E. Synthetic Cannabinoid Use Common Among Pot Smokers. Atlanta, GA: Medscape Medical News, 2012. Available at: http://www.medscape.com/viewarticle/ 762817. Accessed December 28, 2012.
35. Huang PK, Aarde SM, Angrish D, et al. Contrasting effects of D-methamphetamine, 3, 4-methylenedioxymethamphetamine, 3, 4- methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend 2012;126(1):168-175.
36. Johanson CE, Preston K. The influence of an instruction on the stimulus effects of drugs in humans. Exp Clin Psychopharmacol 1998;6(4):427-432.
37. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the Future National Results on Drug Use: 2012 Overview, Key Findings on Adolescent Drug Use. Ann Arbor, MI: Institute for Social Research, The University of Michigan, 2013.
38. Kamata HT, Shima N, Zaitsu K, et al. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 2006;36(8):709-723.
39. Kehr J, Ichinose F, Yoshitake S, et al. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 2011;164(8):1949-1958.
40. Kelly JP. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 2011;3(7-8):439-453.
41. King LA, Kicman AT. A brief history of'new psychoactive substances'. Drug Test Anal 2011;3(7-8):401-403.
42. Kirk JM, Doty P, De Wit H. Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol. Pharmacol Biochem Behav 1998;59(2):287-293.
43. Kirkpatrick MG, Gunderson EW, Johanson CE, et al. Comparison of intranasal methamphetamine and D-amphetamine self-administration by humans. Addiction 2012a; 107(4):783-791.
44. Kirkpatrick MG, Gunderson EW, Perez AY, et al. A direct comparison of the behavioral and physiological effects of methamphetamine and 3, 4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2012b; 219(1):109-122.
45. Kriikku P, Wilhelm L, Schwarz O, et al. New designer drug of abuse: 3, 4-methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci Int 2011;210(1-3):195-200.
46. Martin M, Muller JF, Turner K, et al. Evidence of mephedrone chronic abuse through hair analysis using GC/MS. Forensic Sci Int 2012;218(1-3):44-48.
47. Marusich JA, Grant KR, Blough BE, et al. Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice. Neurotoxicology 2012;33(5):1305-1313.
48. McConnaughey J. Drugs disguised as bath salts send users to ERs. WAFB. Available at: http://www.msnbc.msn. com/id/40797021/ns/healthaddictions. Published December 23, 2010. Accessed December 28, 2012.
49. Meyer MR, Wilhelm J, Peters FT, et al. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatographymass spectrometry. Anal Bioanal Chem 2010;397(3):1225-1233.
50. Mugele J, Nanagas KA, Tormoehlen LM. Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med 2012;60(1):100-102.
51. Nagai F, Nonaka R, Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007;559(2-3):132-137.
52. Ojanpera IA, Heikman PK, Rasanen IJ. Urine analysis of 3, 4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther Drug Monit. 2011 Apr; 33(2):257-63.
53. Penders TM, Gestring R. Hallucinatory delirium following use of MDPV: "bath salts." Gen Hosp Psychiatry 2011;33(5):525-526.
54. Psychonaut Web Mapping Research Group. Mephedrone Report. London, England: Institute of Psychiatry, King's College London, 2009a. Available at: http://www.psychonautproject.eu/documents/reports/Mephedrone.pdf. Accessed December 28, 2012.
55. Psychonaut WebMapping Research Group. MDPV Report. London, England: Institute of Psychiatry, King's College London, 2009b. June 8, 2010. Available at: http://www.psychonautproject.eu/documents/reports/MDPV.pdf. Accessed December 28, 2012.
56. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39(1):32-41.
57. Russo R, Marks N, Morris K, et al. Life-threatening necrotizing fasciitis due to 'bath salts' injection. Orthopedics 2012;35(1):e124-e127.
58. Schifano F, Albanese A, Fergus S, et al. Mephedrone (4- methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 2011;214(3):593-602.
59. Schmidt MM, Sharma A, Schifano F, et al. "Legal highs" on the net-evaluation of UK-based Websites, products and product information. Forensic Sci Int 2011;206(1-3):92-97.
60. Smith C, Cardile AP, Miller M. Bath salts as a "legal high." Am J Med 2011;124(11):e7-e8.
61. Sogawa C, Sogawa N, Ohyama K, et al. Methylone and monoamine transporters: correlation with toxicity. Curr Neuropharmacol 2011;9(1):58-62.
62. Spiller HA, Ryan ML, Weston RG, et al. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol (Phila) 2011;49(6):499-505.
63. Striebel JM, Pierre JM. Acute psychotic sequelae of "bath salts." Schizophr Res 2011;133(1-3):259-260.
64. Substance Abuse and Mental Health Services Administration. Treatment of Stimulant Use Disorders. Treatment Improvement Protocol (TIP) Series, No. 33. Rockville, MD: Center for Substance Abuse Treatment, 2009.
65. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The NSDUH Report: Trends in Adolescent Substance Use and Perception of Risk from Substance Use. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, 2013.
66. Uchiyama N, Kikura-Hanajiri R, Kawahara N, et al. Analysis of designer drugs detected in the products purchased in fiscal year 2006. Yakugaku Zasshi 2008;128(10):1499-1505.
67. United Nations Office on Drugs and Crime (UNODC). UNODC, World Drug Report-2009. New York: United Nations Office on Drugs and Crime; 2009.
68. US Department of Justice, National Drug Intelligence Center. Situation Report: Synthetic Cathinones (Bath Salts): An Emerging Domestic Threat. Product Number 2011-S0787-004. Johnstown, PA: US Department of Justice, National Drug Intelligence Center, 2011.
69. Varner KJ, Daigle K, Weed PF, et al. Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats. Psychopharmacology (Berl). 2013;225(3):675-85.
70. Volkow ND, Wang GJ, Ma Y, et al. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J Neurosci 2003;23(36):11461-11468.
71. Wang Z, Woolverton WL. Estimating the relative reinforcing strength of (+/-)-3, 4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology (Berl) 2007;189(4):483-488.
72. Wiegand TJ, Wax PM, Schwartz T, et al.; on behalf of the Toxicology Investigators Consortium Case Registry Investigators. The Toxicology Investigators Consortium Case Registry-the 2011 experience. J Med Toxicol 2012;8(4):360-377.
73. Winstock AR, Marsden J, Mitcheson L. What should be done about mephedrone? BMJ 2010a; 340: c1605.
74. Winstock A, Mitcheson L, Marsden J. Mephedrone: still available and twice the price. Lancet 2010b; 376(9752):1537.
75. Winstock AR, Mitcheson LR, Deluca P, et al. Mephedrone, new kid for the chop? Addiction 2011a; 106(1):154-161.
76. Winstock AR, Mitcheson LR, Ramsey J, et al. Mephedrone: use, subjective effects and health risks. Addiction 2011b; 106(11):1991-1996.
77. Wood DM, Davies S, Greene SL, et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila) 2010;48(9):924-927.
78. Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 2011;28(4):280-282.
79. Wright M J Jr, Vandewater SA, Angrish D, et al. Mephedrone (4-methylmethcathinone, 4MMC) and D-methamphetamine improve visuospatial associative memory, but not spatial working memory, in rhesus macaques. Br J Pharmacol 2012;167(6):1342-1352.
80. Young AC, Schwarz ES, Velez LI, et al. Two cases of disseminated intravascular coagulation due to "bath salts" resulting in fatalities, with laboratory confirmation. Am J Emerg Med. 2013;31(2):445.
81. Zamengo L, Frison G, Gregio M, et al. Determination of illicit drugs in seized materials: role of sampling and analysis in estimation of measurement uncertainty. Forensic Sci Int 2011;208(1-3):108-123.